Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Myelodysplastic syndrome

Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?

A Correction to this article was published on 24 January 2021

This article has been updated


We conducted a prospective observational study of fit adults aged 60–75 with advanced MDS, enrolled hierarchically for adverse MDS risk (intermediate-2 or high-risk international prognostic score [IPSS], low or intermediate-1 IPSS with poor-risk cytogenetics, or therapy-related MDS) or standard risk with severe cytopenia. A total of 290 patients enrolled at two centers: 175 for adverse risk and 115 for standard risk with severe cytopenia. 113 underwent HCT after a median of 5 months; median follow-up for all was 39.5 months. In univariable analyses, the hazard ratio (HR) for death comparing HCT with no HCT was 0.84 (p = 0.30). The HR for death was 0.64 (p = 0.04) for HCT ≤ 5 months after enrollment and 1.20 (p = 0.39) for HCT > 5 months. In multivariable analyses controlling for age, gender, ECOG performance status, cytogenetic risk, and IPSS risk group, HR for death was 0.75 (p = 0.13) for HCT compared to no HCT, 0.57 (p = 0.01) for adverse MDS risk and 1.33 (p = 0.36) for standard risk with severe cytopenia. In this large, prospective cohort of fit older adults with advanced MDS, we found that survival was significantly improved if HCT was performed early or for adverse risk disease but not for standard risk disease with severe cytopenia.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Simon-Makuch Curves for Overall Survival.
Fig. 2: Simon-Makuch Curves for Overall Survival: Subgroup Analysis by Eligibility Criteria and IPSS.
Fig. 3: Kaplan-Meier Curves for Overall Survival by Entry Criteria and IPSS.
Fig. 4: Which Patients Were Most likely to Benefit from HCT?

Change history


  1. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–64.

    CAS  Article  Google Scholar 

  2. Steensma DP. Myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2015;90:969–83.

    Article  Google Scholar 

  3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    CAS  Google Scholar 

  4. Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93:129–47.

    Article  Google Scholar 

  5. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.

    CAS  Article  Google Scholar 

  6. de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62.

    Article  Google Scholar 

  7. Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31:2662–70.

    Article  Google Scholar 

  8. Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, et al. 5-azacytidine (5-Aza) induction followed by allogeneic stem cell transplantation versus continuous 5-Aza in elderly MDS patients (55–70 years). A prospective randomized study (VidazAllo study). The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards. Bone Marrow Transpl. 2019;54:7–9.

    Article  Google Scholar 

  9. Robin M, Porcher R, Ades L, Raffoux E, Michallet M, Francois S, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome. A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015;29:1496–501.

    CAS  Article  Google Scholar 

  10. Kroger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hubel K, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol. 2017;35:2157–64.

    Article  Google Scholar 

  11. El-Jawahri A, Kim HT, Steensma DP, Cronin AM, Stone RM, Watts CD, et al. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transpl. 2016;51:1121–6.

    CAS  Article  Google Scholar 

  12. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95.

    CAS  Article  Google Scholar 

  13. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–10.

    Article  Google Scholar 

  14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

    CAS  Article  Google Scholar 

  15. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536–47.

    CAS  Article  Google Scholar 

  16. Kim HT, Gray R. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials. Clin Trials. 2012;9:155–63.

    Article  Google Scholar 

  17. Mantel NB, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974;69:81–6.

    Article  Google Scholar 

  18. Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Methods Psychiatr Res. 2002;11:68–74.

    Article  Google Scholar 

  19. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3:35–44.

    CAS  Article  Google Scholar 

  20. van Houwelingen HC, Putter H. Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukemia data. Lifetime Data Anal. 2008;14:447–63.

    Article  Google Scholar 

  21. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710–9.

    CAS  Article  Google Scholar 

  22. Murillo A, Cronin AM, Laubach JP, Hshieh TT, Tanasijevic AM, Richardson PG, et al. Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. J Geri Oncol. 2018.

  23. Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2002;99:4370–8.

    CAS  Article  Google Scholar 

  24. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997–2004.

    CAS  PubMed  Google Scholar 

  25. Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, et al. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. Bone Marrow Transpl. 2017;52:1107–12.

    CAS  Article  Google Scholar 

  26. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–46.

    CAS  Article  Google Scholar 

  27. Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, et al. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. PLoS One. 2013;8:e74368.

    CAS  Article  Google Scholar 

  28. Abel GA, Koreth J. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Curr Opin Hematol. 2013;20:150–6.

    Article  Google Scholar 

  29. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–85.

    CAS  Article  Google Scholar 

  30. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

    CAS  Article  Google Scholar 

Download references


This work was supported by a Leukemia and Lymphoma Society Research Scholar Grant (GAA), an American Cancer Society Clinical Scholar Award (GAA), an NCI P01 Award (1P01CA229092-01A1; RJS and HK), and an NCI/NIH T32 Grant (CA092203; AH). This work was presented in preliminary form at the American Society of Hematology 2018 Annual Meeting, Abstract #972.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Gregory A. Abel.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: We have noticed a minor error in Figure 3 of the online document, which we introduced during our last corrections of the proofs when you asked us to add in a description of each panel for the figure. Everything is correct except in the description/legend at the bottom, to match the label above each panel, it should read “Fig. 3 Kaplan-Meier Curves for Overall Survival by Entry Criteria and IPSS. a Depicts overall survival for all patients by eligibility criteria (adverse MDS risk versus standard risk with severe cytopenia) and b for only those NOT undergoing HCT. c Depicts overall survival for all patients by IPSS risk (low or intermediate-1 versus intermediate-2 or high-risk disease) and d for only those NOT undergoing HCT. Log-rank testing was used for group comparison.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abel, G.A., Kim, H.T., Hantel, A. et al. Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. Leukemia 35, 1166–1175 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links